Celgene, Agios extend collaboration as AG-221 impresses at ASH 2014
This article was originally published in Scrip
Executive Summary
Agios Pharmaceuticals reached a new high of $107.30 on 8 December after the San Francisco-based developer of drugs targeting cancer metabolism said Celgene extended the companies' partnership again following positive Phase I results in advanced hematological malignancies for AG-221.
You may also be interested in...
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.